RenovoRx Announces New Board of Directors Members

RenovoRx is thrilled to announce that Klaus W. Hambuechen, Laurence Marton, MD, and Una Ryan, PhD, have joined Marta Gaia Zanchi, PhD, CEO and Dr. Ramtin Agah, MD, CMO on the Company’s Board of Directors.

RenovoRx is thrilled to announce that Klaus W. Hambuechen, Laurence Marton, MD, and Una Ryan, PhD, have joined Marta Gaia Zanchi, PhD, CEO and Dr. Ramtin Agah, MD, CMO on the Company’s Board of Directors. Our three new members bring to the Board their vision, outstanding wealth of expertise and in-depth knowledge of the medical device, biotechnology and pharmaceutical industries, as well as their extensive global network of healthcare professionals and business leaders.

Recent News

TAMP-Mediated Gemcitabine Lowers Systemic Exposure vs IV Delivery in Locally Advanced Pancreatic Cancer

A pharmacokinetic sub-study of the phase 3 TIGeR-PaC trial shows TAMP-delivered gemcitabine significantly lowers systemic exposure compared to standard IV delivery in locally advanced pancreatic cancer.

RenovoRx Reports Record Second Quarter 2026 Results, Driven by Accelerating Commercial Adoption and 61% Sequential Quarterly Revenue Growth

RenovoRx today announced its financial results for the second quarter ended June 30, 2026, and provided shareholders with a business update highlighting continued commercial momentum and clinical progress.

RenovoRx Achieves Major Milestone with Full Enrollment in Phase III TIGeR-PaC Trial for Locally Advanced Pancreatic Cancer

RenovoRx is pleased to announce completion of enrollment in the Company’s Phase III TIGeR-PaC trial in locally advanced pancreatic cancer (LAPC).

RenovoRx Announces First Commercial Clinical Use of RenovoCath® in Sarcoma Patient Treatment, Marking Expansion of Targeted Drug-Delivery Device to Other Solid Tumors

RenovoRx today announced the first commercial clinical use of RenovoCath for drug-delivery in the treatment of a patient with sarcoma at the CARTI Cancer Center Little Rock (“CARTI”).